Since my previous article, shares of Abbott Laboratories have returned 10 ... It's just not up to par with what I would need to see to maintain my buy rating. I would need to see a pullback to ...

Abbott has a diversified business, exciting growth avenues, and a strong dividend program. The company faces potential obstacles, including legal problems and stiff competition. However, that's no ...

If a company's history and track record were good enough reasons to buy its shares, it'd be easy to make a case for investing in Abbott Laboratories (NYSE: ABT). Abbott is a longtime leader in the ...

The ABBOTT PRISM system is intended for in vitro diagnostic use only. A high throughput, highly automated test system for blood screening: The ABBOTT PRISM is a fully automated, high-volume blood ...

Citi reaffirmed its positive stance on Abbott Laboratories (NYSE:ABT), maintaining a Buy rating and a price target of $127.00. The endorsement follows updates from the company's management ...

Analyst Larry Biegelsen from Wells Fargo maintained a Buy rating on Abbott Laboratories (ABT – Research Report) and keeping the price target at $133.00. Larry Biegelsen has given his Buy rating ...

Ausria, a radioimmunoassay test to detect serum hepatitis, was launched in 1972 and marked the beginning of Abbott's immunodiagnostics business. A year later, the Abbott Diagnostics Division was ...

In a report released today, Joanne Wuensch from Citi maintained a Buy rating on Abbott Laboratories (ABT – Research Report). The company’s shares closed yesterday at $117.82. According to ...